Sensus Healthcare Fourth Quarter 2022 Financial Results Include Quarterly Revenues of $13.1 Million Full-year revenues increased 65% to $44.5 million Investments in technology and staff position Sensus for growth in 2023

Sensus Healthcare Fourth Quarter 2022 Financial

Quarterly Revenues of $13.1 Million

Full-year revenues increased 65% to $44.5

Investments in technology and staff position

Sensus for growth in 2023 and beyond

Conference call begins at 4:30 p.m. Eastern

BOCA RATON, Fla. (February 9, 2023) -

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive

and cost-effective treatments for oncological and non-oncological conditions (Company or Sensus), announces financial results for the

three and 12 months ended December 31, 2022.

Highlights from the fourth quarter of 2022 and

recent weeks include the following (all comparisons are with the fourth quarter of 2021, unless otherwise indicated):

Management Commentary

"During the fourth quarter we executed well

on our strategy and once again delivered strong revenues and profits," said Joe Sardano, chairman and

chief executive officer of Sensus Healthcare. "We took a number of steps to position Sensus for future success. These included assembling

the staff and strategies to drive sustainable and consistent growth, building inventory, acquiring new aesthetic products that will be

submitted to FDA for anticipated clearance in the latter half of 2023, further investing in our Sentinel IT Solutions capability

and increasing sales and marketing programs, headcount and capabilities. With better reimbursement for superficial radiation therapy (SRT)

and lower reimbursement for Mohs surgery, along with data suggesting that one in five Americans will develop skin cancer, we have powerful

tailwinds to support our programs."

"While maintaining focus on our core dermatology

business and providing products our customers need and want, radiation oncology is an avenue for growth. We are gaining awareness among

radiation oncologists and recently sold an SRT-100 Vision system to a luminary hospital in the northeast. We launched important

upgrades to this premium system that include new state-of-the-art, solid-state, high-frequency ultrasound, which provides the industry's

best view of the epidermis and utilizes a new ergonomically designed probe with single-use disposables. This upgraded system is garnering

interest among physicians, and helped by design changes and our fair market leasing program, the Vision has become our leading SRT product.

Our physicians have the ability to 'See what they Treat' which helps to reassure patients."

Mr. Sardano added, "We announced several important

hires and promotions earlier this year, including adding a dedicated Aesthetic Sales division, beefing up our Quality and Regulatory team

for the growth activities in 2023, along with the promotions of Emiliano Sosa to Chief Technical Officer and Maggie Martinez to Chief

Operating Officer. We have an exceptional team in place to support our growth trajectory with thoughtful programs, efficiency and leadership.

We are deploying capital to invest in Sensus, planning to develop and continuing to acquire new technologies, adding to our sales force

and having repurchased $3.0 million in our own stock. We are excited to continue executing our aggressive business plan efficiently and

Fourth Quarter Financial Results

Revenues for the fourth quarter of 2022 were $13.1

million, compared with $13.0 million for the fourth quarter of 2021.

Cost of sales for the fourth quarter of 2022 was

$4.8 million, compared with $4.2 million for the prior-year quarter. The increase was mostly due to higher manufacturing costs in the

2022 period, reflecting inflation.

Gross profit for the fourth quarter of 2022 was

$8.4 million, or 63.7% of revenues, compared with $8.9 million, or 68.0% of revenues, for the fourth quarter of 2021. The decrease was

primarily driven by higher manufacturing costs in 2022.

Selling and marketing expense for the fourth quarter

of 2022 was $1.6 million, compared with $1.3 million for the fourth quarter of 2021. The increase was attributable to advertising expense

and compensation expense due to increased headcount.

General and administrative expense for the fourth

quarter of 2022 was $1.4 million, compared with $1.1 million for the fourth quarter of 2021. The increase was primarily due to higher

professional fees, higher compensation, and bad debt expense.

Research and development expense for the fourth

quarter of 2022 was $1.2 million, unchanged from the prior-year quarter.

Provision for income taxes was $1.6 million for

the fourth quarter of 2022, compared with no income tax provision for the prior-year quarter.

Net income for the fourth quarter of 2022 was

$2.8 million, or $0.17 per diluted share, compared with $5.3 million, or $0.32 per diluted share, for the fourth quarter of 2021.

Adjusted EBITDA for the fourth quarter of 2022

was $4.3 million, compared with $5.6 million for the fourth quarter of 2021. Adjusted EBITDA, a non-GAAP financial measure, is defined

as earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between

GAAP and non-GAAP financial measures, and the specific reasons these non-GAAP financial measures are provided.

Cash and cash equivalents were $25.5 million as

of December 31, 2022, compared with $14.5 million as of December 31, 2021. The Company had no outstanding borrowings under its revolving

line of credit as of December 31, 2022 or December 31, 2021.

Full Year Financial Results

Revenues for 2022 were $44.5 million, compared

with $27.0 million for 2021. The 65% increase was driven by a higher number of units sold in 2022 as the demand increased.

Cost of sales for 2022 were $14.9 million, compared

with $10.1 million for 2021, reflecting the higher number of units sold.

Gross profit for 2022 was $29.6 million, or 66.5%

of revenue, compared with $17.0 million, or 62.8% of revenue, for 2021. The increases were driven by a higher number of units sold in

2022 and service revenue on installed units.

Selling and marketing expense for 2022 was $6.3

million, compared with $4.8 million for 2021. The increase was primarily attributable to higher spending on marketing activities, and headcount.

General and administrative expense for 2022 was

$5.0 million, compared with $4.6 million for 2021. The increase was primarily due to higher compensation and bad debt expense.

Research and development expense for 2022 was

$3.5 million, compared with $3.4 million for 2021. The Company expects research and development expense in 2023 to be generally consistent

The Company reported other income for 2022 of

$13.2 million, compared with $0.01 million for 2021. The increase was mostly related to a gain on the sale of a non-core asset.

Net income for 2022 was $24.2 million, or $1.46

per diluted share, compared with $4.1 million, or $0.25 per diluted share, in 2021. Net income for 2022 excluding a gain on the sale of

a non-core assets was $11.5 million, or $0.69 per diluted share.

Adjusted EBITDA for 2022 was $28.1 million, compared

with $5.1 million for 2021.

Use of Non-GAAP Financial Information

This press release contains supplemental financial

information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP).

Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis of the Company's performance. Adjusted

EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined

in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes the impact of interest, income taxes,

depreciation, amortization and stock-compensation expense, provides useful supplemental information that is essential to a proper understanding

of the financial results of Sensus Healthcare. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use

calculation methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes

that Adjusted EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude

items that may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided

in the schedule below.

SENSUS HEALTHCARE, INC.

GAAP TO NON-GAAP RECONCILIATION

Conference Call and Webcast

Sensus Healthcare will host an investment community